Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Rhea-AI Summary
Red Light Holland (OTCQB: TRUFF) completed its acquisition of Filament Health effective April 29, 2026, creating a vertically integrated psychedelic platform combining Filament's pharmaceutical-grade R&D, a Health Canada Dealer's License, and a portfolio of 70+ patents with Red Light's global distribution.
The transaction issued 99,180,497 consideration shares plus 70,836,683 shares for debt settlement, leaving 595,727,901 Red Light shares outstanding and former Filament holders owning approximately 30%.
Positive
- Adds >70 patents and proprietary extraction technologies
- Acquires Health Canada Dealer's License enabling regulated development
- Strengthens IND-enabled clinical pipeline including PEX010
- Creates vertically integrated R&D-to-distribution platform
- Former Filament shareholders hold ~30% ownership post-close
Negative
- Total shares outstanding increased to 595,727,901 (dilution)
- Issued 70,836,683 shares to settle Filament debt (additional dilution)
- Consideration shares subject to timed resale restrictions (6/9/12 months)
- 13,683,559 consideration shares escrowed for 12 months (indemnity holdback)
News Market Reaction – TRUFF
In the Apr 30 session, TRUFF gained 0.69%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution
- Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies
- Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities
- Positions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industry
- Advances clinical pipeline, including PEX010, while expanding access to natural psilocybin products globally
- Establishes a regulated pipeline of psychedelic compounds, including ibogaine, MDMA, and psilocybin, supporting next-generation drug discovery and IND-enabled clinical development within compliant frameworks
Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce, further to their joint press releases dated March 10, 2026 (the "March 10 Release"), March 23, 2026, April 27, 2026 and April 29, 2026, that effective April 29, 2026, Red Light has acquired all the issued and outstanding common shares of Filament ("Filament Shares"), pursuant to a statutory plan of arrangement (the "Arrangement" or the "Transaction") under the Business Corporations Act (British Columbia). Capitalized terms not otherwise defined herein have the meanings attributed to them in the March 10 Release.
With the closing of the Transaction, Red Light has acquired all issued and outstanding Filament Shares, creating a vertically integrated platform focused on the development, commercialization, and global distribution of natural psychedelic products and pharmaceutical-grade botanical drug candidates under established regulatory frameworks, including U.S. Food and Drug Administration ("FDA") clinical development pathways and Investigational New Drug ("IND") programs.
Key Transaction Highlights:
- Industry-Leading Platform: Combines Red Light's global distribution footprint and brand strength with Filament's pharmaceutical-grade drug development capabilities
- Regulatory Advantage: Filament operates under a Health Canada Dealer's License, permitting the legal extraction, synthesis, study, and production of controlled psychedelic compounds, including psilocybin, MDMA, and ibogaine, while advancing programs aligned with FDA IND requirements
- Extensive Intellectual Property: Adds Filament's portfolio of over 70 patents and proprietary technologies focused on natural psychedelic extraction, standardization, and formulation
- Clinical Advancement: Strengthens development of PEX010, Filament's lead botanical drug candidate, currently in active IND-enabled studies
- Validated Scientific Platform: Supported by over 70 ongoing and completed studies with leading academic institutions such as University of British Columbia, Johns Hopkins University, and Imperial College London, reinforcing a robust, science-driven foundation for drug discovery and clinical development
- Global Growth Strategy: Positions the combined company to pursue regulated pharmaceutical markets alongside emerging consumer and compassionate access channels
- First-Mover Advantage: Establishes a differentiated leader focused on natural (non-synthetic) psychedelic solutions within compliant regulatory pathways
Management Commentary:
"This is an inflection point for Red Light," said Todd Shapiro, CEO & Director of Red Light. "With the addition of Filament and its extensive intellectual property portfolio, including over 70 patents, combined with our expanding global distribution footprint, IND-enabled capabilities, and a Health Canada Dealer's License allowing for the legal study of compounds like psilocybin and ibogaine, we are exceptionally well-positioned to help shape the future of this industry. The growing and undeniable momentum behind psychedelic medicine, supported by science and evolving regulatory and progressive governmental signals, brings us closer to our goal of improving lives at scale. As the industry truly transitions from underground to mainstream, we will continue playing a leading role."
"Joining forces with Red Light represents a transformative step forward," said Benjamin Lightburn, CEO of Filament. "We have built a platform grounded in rigorous science, strong intellectual property, and regulatory compliance, including multiple open INDs. Through our Health Canada Dealer's License, we are able to legally develop and study botanical psychedelic drug candidates derived from compounds such as psilocybin and ibogaine. By combining this foundation with Red Light's commercialization expertise and global reach, we are uniquely positioned to accelerate innovation, support clinical advancement, and responsibly expand access to natural psychedelic therapies worldwide."
Transaction Details:
Under the terms of the Arrangement Agreement, each outstanding Filament Share was exchanged for Consideration Shares of Red Light, based on an exchange ratio of 0.36634769 and a deemed price of
In addition, holders of Filament options and warrants will receive, upon exercise, the same consideration they would have received as if they were Filament shareholders at the effective time of the Transaction.
In connection with closing of the Arrangement, (i) 13,683,559 Consideration Shares, totalling approximately
The Consideration Shares issued in the Arrangement are subject to resale restrictions, with
Pursuant to the letter of transmittal mailed to certain Filament shareholders as part of the materials in connection with the annual general and special meeting of shareholders of Filament held on April 24, 2026, in order to receive the portion of the consideration to which they are entitled, registered holders of Filament Shares are required to deposit their share certificate(s) representing Filament Shares, together with a duly completed letter of transmittal, with Odyssey Trust Company, the depositary under the Arrangement.
Further information about the closing of the Arrangement is available on the SEDAR+ profile of Red Light on SEDAR+ at www.sedarplus.ca.
Financial and Legal Advisors
Garfinkle Biderman LLP acted as legal counsel for Red Light. Evans and Evans, Inc. provided a fairness opinion to the board of directors of Filament in connection with the Arrangement and Fasken Martineau DuMoulin LLP acted as legal counsel for Filament.
Strategic Vision
Following closing, the combined company will continue to operate with a focus on advancing IND-enabled research, regulated clinical development programs, and commercial expansion, while maintaining strict compliance with applicable regulatory frameworks.
The completion of this Transaction marks a defining milestone in the evolution of Red Light, transitioning from a consumer-focused company into a fully integrated, regulatory-aligned psychedelic platform with capabilities across:
- Research & Development
- Controlled Substance Licensing & Compliance
- IND Programs
- Clinical Trial Design & Regulatory Strategy
- Intellectual Property & Drug Discovery
- Consumer Product Distribution
Together, Red Light and Filament aim to bridge the gap between pharmaceutical innovation and real-world access, positioning the combined entity to capitalize on the accelerating global shift toward legal, science-backed psychedelic therapies, while advancing programs designed to meet FDA and international regulatory standards.
Additional Early Warning Disclosure of Red Light
In accordance with the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), Red Light announces that it has acquired beneficial ownership and control over 270,728,040 Filament Shares, which represents
Additional Early Warning Disclosure of Former Filament Shareholders
Immediately prior to the closing of the Arrangement and the transactions related thereto, Benjamin Lightburn and Negev Capital Fund One LP held 76,439,539 (
About Red Light Holland:
Red Light Holland is an Ontario-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.
About Filament Health:
Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.
For additional information on Red Light Holland:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlight.co
Website: www.RedLight.co
For additional information on Filament:
Benjamin Lightburn
Chief Executive Officer & Director
Tel: 604-500-2407
Email: ben@filament.health
Website: www.filament.health
Cautionary Note Regarding Forward-Looking Statements:
Certain information in this news release constitutes "forward-looking information" within the meaning of applicable Canadian securities laws ("forward-looking information"). Forward-looking information is based on management's reasonable assumptions, estimates and expectations as of the date hereof and is often identified by words such as "expect", "anticipate", "intend", "plan", "believe", "estimate", "may", "will", "could", "would" and similar expressions.
Forward-looking information in this news release includes, but is not limited to, statements regarding: (i) the anticipated benefits, strategic rationale and expected impact of the Arrangement on Red Light and its business; (ii) the combined company's plans, objectives and strategy following closing, including the advancement of clinical development programs and any IND-enabled activities; (iii) expectations regarding integration of operations, intellectual property, infrastructure and personnel; (iv) expectations regarding the continued operation of Filament's business and the use of regulatory licences and permits following closing; (v) any expectations regarding commercialization, distribution and market expansion; and (vi) any statements regarding future plans, objectives, expectations or results.
Forward-looking information is based on certain assumptions, including, without limitation: that the parties will be able to implement post-closing integration plans on the timelines currently contemplated; that Red Light will be able to retain key personnel and maintain key relationships following closing; that the combined business will be able to operate in compliance with applicable laws and regulatory requirements (including with respect to controlled substances and clinical development); and that general business and market conditions will remain substantially consistent with management's expectations.
Forward-looking information involves known and unknown risks and uncertainties that may cause actual results to differ materially, including, without limitation: risks associated with integration and realizing anticipated benefits of the Arrangement; risks inherent in clinical drug development (including delays, costs, regulatory requirements and the possibility of negative or inconclusive results); changes in laws, regulations or government policies applicable to psychedelic substances in Canada and internationally; the risk that the combined business does not achieve the anticipated strategic objectives or timelines; the ability to retain key personnel; the availability of capital and liquidity; and general economic, market and business conditions. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, Red Light and Filament do not undertake to update or revise any forward-looking information.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295136